HEALTH● LOWJul 23 · Jul 23, 2026, 10:45 AM
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
CNBC
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH19m agoAMDO Strike: Medical activities partially paralysed in OyoVanguard NigeriaHEALTH26m agoOpen enrollment begins: What Medicare beneficiaries need to know for 2027The HillHEALTH26m agoOzempic users may face protein, vitamin D deficiencies, experts warnThe HillHEALTH28m agoJ&J reports 75% tumor response rate with novel prostate cancer therapySeeking Alpha Tech